ERBB2 T798M

CI-VAR-00004344Explore in graph →NP_004439.2:p.Thr798MetNM_004448.3:c.2393_2394delinsTGCIViC 1305

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
ERBB2 T798M	Lapatinib	Predictive	D	Supports Resistance	2	accepted	EID3006 Cell proliferation analysis of Ba/F3 cells expressing ERBB2-T798M showed IC50 value of 1433nM, and was considered as lapatinib-resistant. PMID 22046346 · Kancha et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.